News

News

Hear what the media is saying about Vistagen Therapeutics, and the products we are developing to exceed the current standard of care.

Media Coverage

Bio Report logo
The Bio Report: A Rapid Onset Nasal Spray to Treat Mental Health Conditions
Read
The Biotech Project
The Biotech Project: Featuring Shawn Singh
Read
BioSpace Logo
Combatting the Mental Health Crisis with an Acute Treatment Nasal Spray
Read

Press Releases

Small U.S. Phase 1 trial with newly optimized formulation to confirm favorable safety profile from three previous clinical trials and facilitate Phase 2B development of PH10 as a stand-alone treatment for major depressive disorder SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan.
Topline results of the exploratory Phase 2 clinical study anticipated in Q1 2023 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 10, 2023-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety,
Vistagen’s recent patent filings in the U.S. and numerous additional countries mark the next step in the Company’s ongoing efforts to enhance potential commercial protection across its CNS pipeline in key pharmaceutical markets SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec.
Vistagen’s acquisition of Pherin will eliminate all future royalty and milestone payment obligations related to PH94B and PH10 and add three new pherine drug candidates to Vistagen’s pipeline SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec. 21, 2022-- Vistagen (Nasdaq: VTGN), a late